Shares of Merck KGaA (FRA:MRK) have been assigned an average rating of “Hold” from the twenty-one brokerages that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is €98.70 ($114.77).
Several analysts have commented on MRK shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Merck KGaA in a research note on Wednesday, September 19th. Credit Suisse Group set a €93.00 ($108.14) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, October 23rd. UBS Group set a €115.00 ($133.72) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, October 17th. Kepler Capital Markets set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Friday, October 19th. Finally, Barclays set a €72.00 ($83.72) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research note on Tuesday, October 9th.
Shares of MRK traded up €0.18 ($0.21) during mid-day trading on Friday, reaching €90.72 ($105.49). 349,445 shares of the company’s stock were exchanged. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: What is a balanced fund?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.